01 — Identity
What Is FOX04-DRI?
Origin
Developed by Dr. Peter de Keizer at Erasmus MC Rotterdam, Netherlands. Published in Cell, 2017.
Chemical Class
D-retro-inverso peptide — uses D-amino acids in reverse sequence, conferring protease resistance and cell-penetrating ability.
Primary Use
Selective elimination of senescent ("zombie") cells. Targets the FOXO4-p53 survival mechanism unique to senescent cells.
Administration
Subcutaneous injection. Pulsed protocol — NOT daily. 3 consecutive days on, then weeks off.
FOX04-DRI works by mimicking the FOXO4 binding domain. In senescent cells, FOXO4 traps p53 in the nucleus — preventing the cell from dying. FOX04-DRI disrupts this interaction, freeing p53 to trigger apoptosis specifically in senescent cells. Normal healthy cells are spared because they don't rely on FOXO4-p53 nuclear retention for survival.
02 — Research History
Discovery & Research Timeline
2004–2014
Research into cellular senescence matures. The "senescence-associated secretory phenotype" (SASP) — the toxic inflammatory cocktail secreted by zombie cells — is characterized by Judith Campisi's lab at the Buck Institute. Senescent cells are identified as drivers of aging, cancer risk, and chronic disease.
2016
Dr. Peter de Keizer's lab at Erasmus MC identifies FOXO4 as the survival factor keeping senescent cells alive. Senescent cells uniquely upregulate FOXO4, which sequesters p53 in the nucleus — blocking the apoptosis signal. Normal cells do not depend on this mechanism.
2017
Landmark Cell paper published: "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging." FOX04-DRI injections in naturally aged mice and chemotherapy-treated mice restore physical fitness, fur density, and organ histology. Median lifespan extension observed.
2018–2020
Follow-up research confirms FOX04-DRI clears senescent cells in liver fibrosis models, renal aging models, and hair follicle senescence. Collaborating groups attempt to identify optimal dosing windows and pulse frequency.
2021–2024
Research peptide community adopts FOX04-DRI as a longevity protocol compound. Anecdotal human use grows. No human clinical trials published. Dr. de Keizer's group continues preclinical work; commercialization pathway remains unclear.
03 — Primary Benefits
Documented Effects
01
Senescent Cell Clearance
Selectively eliminates FOXO4-expressing senescent cells via targeted apoptosis — without harming healthy, non-senescent cells. The most targeted senolytic mechanism identified to date.
02
SASP Reduction
Removes the source of the senescence-associated secretory phenotype — the pro-inflammatory cytokine storm (IL-6, IL-8, MMP-3, PAI-1) that drives systemic aging and tissue dysfunction.
03
Physical Function Restoration
Aged mice treated with FOX04-DRI showed significant improvements in running speed, grip strength, and endurance — reverting to phenotypes resembling younger animals.
04
Organ Histology Improvement
Liver and kidney tissue from treated mice showed reduced fibrosis and normalized cellular architecture compared to untreated age-matched controls.
05
Hair Follicle Regeneration
Clearance of senescent cells in hair follicle niches allowed dormant follicles to re-enter the growth phase. Fur density restoration was one of the most visually striking findings in the 2017 paper.
06
Chemotherapy Recovery
Mice with chemotherapy-induced senescence burden showed accelerated recovery of physical function and reduced frailty after FOX04-DRI treatment — suggesting a post-cancer application.
07
Anti-Fibrotic
Senescent cells are major drivers of organ fibrosis. FOX04-DRI reduces liver and kidney fibrosis in animal models by clearing the senescent fibroblasts responsible for excess collagen deposition.
04 — Reconstitution
Mixing & Storage
▸ Standard Reconstitution — 10mg Vial
10mg vial + 300 units BAC water = 33.3 mcg per unit on insulin syringe
10,000 mcg total per vial · Refrigerate after reconstitution · Use within 4–6 weeks · Protect from light
FOX04-DRI is a D-retro-inverso peptide — it uses D-amino acids which are more resistant to protease degradation than standard L-amino acid peptides. This contributes to its stability in solution. Still handle with standard peptide storage protocols.
UNRECONSTITUTED
Refrigerate at 2–8°C. Stable at room temperature for short-term shipping. Do not freeze lyophilized powder.
RECONSTITUTED
Refrigerate at 2–8°C. Use within 4–6 weeks. Keep away from light. Do not freeze liquid solution.
05 — Dosing Protocol
Dose Levels & Unit Draws
| Level | Dose | Syringe Draw | Description |
|---|
| LOW |
1mg 30 units on insulin syringe |
30u |
Starting/exploratory dose. Assess tolerance and response. Good for first pulse cycle. |
| STANDARD |
2mg 60 units on insulin syringe |
60u |
Most commonly referenced research dose. Used in de Keizer lab protocols and most anecdotal human reports. |
| HIGH |
5mg 150 units on insulin syringe |
150u |
Intensive senolytic protocol. Used 3 consecutive days per pulse. Higher dose may increase apoptotic burden — monitor inflammatory response (temporary SASP flare possible). |
⚠ PULSED PROTOCOL ONLY — NOT DAILY. FOX04-DRI is administered in 3-consecutive-day pulses, then a multi-week break. Daily continuous use is not the protocol and may cause excessive apoptotic burden. Think of it as a periodic cellular "cleanup" — not a daily maintenance peptide. Most protocols: one 3-day pulse per month or every 4–6 weeks.
06 — Timing & Frequency
When & How Often
| Variable | Recommendation | Why |
|---|
| Pulse Duration |
3 consecutive days |
3-day pulse matches the protocol from the 2017 Cell paper. Sustained presence over 3 days ensures maximal senescent cell clearance in the current senescent cell population before cycling off. |
| Break Between Pulses |
2–6 weeks off |
Allows the body to clear apoptotic debris, resolve any transient inflammatory response, and for new senescent cells to accumulate before the next clearance pulse. |
| Annual Frequency |
3–6 pulse cycles/year |
Most longevity protocols target 3–6 pulses annually. More frequent use has no established benefit and the senescent cell accumulation rate doesn't warrant monthly clearance in most users. |
| Time of Day |
AM preferred |
No strong mechanistic rationale for specific timing. AM dosing is conventional and allows observation of any immediate response. |
| Fasted vs Fed |
Either acceptable |
FOX04-DRI mechanism is not dependent on insulin or metabolic state. Fasted AM is conventional but not required. |
| Injection Site |
SC abdomen or thigh |
Subcutaneous injection. Distributes systemically — no need for site-specific targeting. Rotate sites across the 3 days. |
07 — Biomarker Monitoring
Lab Tests & Optimal Ranges
▸ Senescence Markers
| Biomarker | Lab Test | Clinical Range | Optimal Range |
|---|
GDF-15
Mitochondrial/senescence stress |
Serum GDF-15 |
CLINICAL<1200 pg/mL |
OPTIMAL<400 pg/mL |
p21 / CDKN1A
Senescent cell cycle arrest marker |
Research panel (specialty lab) |
CLINICALLab-dependent |
OPTIMALDeclining with treatment |
▸ Inflammatory / SASP Panel
| Biomarker | Lab Test | Clinical Range | Optimal Range |
|---|
| hsCRP |
High-Sensitivity CRP |
CLINICAL<3.0 mg/L |
OPTIMAL<0.5 mg/L |
| IL-6 |
Serum IL-6 |
CLINICAL<7.0 pg/mL |
OPTIMAL<1.5 pg/mL |
| TNF-alpha |
Serum TNF-α |
CLINICAL<8.1 pg/mL |
OPTIMAL<2.0 pg/mL |
Fibrinogen
SASP-driven coagulation marker |
Serum fibrinogen |
CLINICAL200–400 mg/dL |
OPTIMAL<250 mg/dL |
▸ Safety Panel
| Biomarker | Lab Test | Clinical Range | Optimal Range |
|---|
| AST / ALT |
CMP |
CLINICALAST 10–40 / ALT 7–56 U/L |
OPTIMALAST <26 / ALT <26 U/L |
| CBC |
Complete Blood Count |
CLINICALStandard ranges |
OPTIMALMid-range; WBC 4.5–6.0 |
| Creatinine / eGFR |
CMP |
CLINICALCreat 0.7–1.3 / eGFR >60 |
OPTIMALCreat 0.8–1.1 / eGFR >90 |
⚠ FOX04-DRI is experimental. The landmark 2017 Cell paper used mouse models. No published human clinical trials exist. The SASP inflammatory burden may transiently increase immediately after a pulse cycle as dying senescent cells release their contents — this is expected and resolves within days. Monitor hsCRP and IL-6 before and 1–2 weeks after each pulse. Individuals with autoimmune conditions should consult a physician before use.
08 — Cycle Protocol
Pulse Schedule & Protocol
GENERAL LONGEVITY
3 Days On
3 consecutive daily injections (Day 1, 2, 3) at 1–2mg per day. Then 4–6 weeks off. Repeat 3–4 times per year for longevity maintenance.
INTENSIVE SENOLYTIC
3 Days × 5mg
High-dose 3-day pulse at 5mg/day for accelerated clearance. Minimum 6-week break. Monitor inflammatory markers post-pulse. Max 2–3 cycles per year at this dose.
FOX04-DRI should NOT be stacked with other pro-apoptotic compounds during the pulse window. It can be run alongside daily longevity peptides (SS-31, GHK-Cu, Epitalon) during the off weeks — just pause those during the 3-day pulse to avoid confounding inflammatory signals.